Literature DB >> 16988453

Adjuvant properties of CpG oligonucleotides in primates.

Daniela Verthelyi1.   

Abstract

Unlike mammalian DNA, bacterial, plasmid, and synthetic DNA containing unmethylated CpG dinucleotides in specific sequence contexts are recognized by the Toll-like receptor 9 expressed by B cells and plasmacytoid dendritic cells, and trigger the activation of the innate and adaptive immune system. Upon signaling, CpG DNA induces B cells, natural killer cells, macrophages, and dendritic cells to proliferate, differentiate, take up, and present antigen and secrete a variety of immunoglobulins, chemokines, and predominantly Th1-type cytokines. Preclinical studies in mice and primates show that DNA sequences containing CpG motifs can selectively promote cellular and/or humoral immune responses in vivo. Early results from ongoing clinical studies indicate that CpG oligonucleotides (ODN) are well tolerated and improve the immune response to microbial vaccines. This work examines the progress in utilizing CpG ODN as adjuvants in conventional and DNA vaccines.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16988453     DOI: 10.1385/1-59745-168-1:139

Source DB:  PubMed          Journal:  Methods Mol Med        ISSN: 1543-1894


  5 in total

1.  Cutting edge: a TLR9 cytoplasmic tyrosine motif is selectively required for proinflammatory cytokine production.

Authors:  Annapoorani Chockalingam; William Alfred Rose; Maroof Hasan; Chia-Hsin Ju; Cynthia Anne Leifer
Journal:  J Immunol       Date:  2011-12-14       Impact factor: 5.422

2.  Intranasal immunization with chlamydial protease-like activity factor and CpG deoxynucleotides enhances protective immunity against genital Chlamydia muridarum infection.

Authors:  Yu Cong; Madhulika Jupelli; M Neal Guentzel; Guangming Zhong; Ashlesh K Murthy; Bernard P Arulanandam
Journal:  Vaccine       Date:  2007-02-23       Impact factor: 3.641

3.  Mucosal adjuvanticity of fibronectin-binding peptide (FBP) fused with Echinococcus multilocularis tetraspanin 3: systemic and local antibody responses.

Authors:  Zhisheng Dang; Jinchao Feng; Kinpei Yagi; Chihiro Sugimoto; Wei Li; Yuzaburo Oku
Journal:  PLoS Negl Trop Dis       Date:  2012-09-27

4.  A pilot study on developing mucosal vaccine against alveolar echinococcosis (AE) using recombinant tetraspanin 3: Vaccine efficacy and immunology.

Authors:  Zhisheng Dang; Kinpei Yagi; Yuzaburo Oku; Hirokazu Kouguchi; Kiichi Kajino; Jun Matsumoto; Ryo Nakao; Hiroyuki Wakaguri; Atsushi Toyoda; Hong Yin; Chihiro Sugimoto
Journal:  PLoS Negl Trop Dis       Date:  2012-03-27

Review 5.  Engineering DNA vaccines against infectious diseases.

Authors:  Jihui Lee; Shreedevi Arun Kumar; Yong Yu Jhan; Corey J Bishop
Journal:  Acta Biomater       Date:  2018-08-31       Impact factor: 8.947

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.